Congratulations to Dr Liesl Butler on Albert Baikie Memorial Medal

Dr Liesl Butler is a junior haematologist pursuing a career in molecular pathology. She is currently undertaking translational research in the area, having started a PhD in 2019 at the Australian Centre for Blood Diseases, Monash University and Alfred Health, supervised by Professor Andrew Perkins. Her project focuses on the development of improved biomarkers and targeted therapy for the myeloproliferative neoplasms (MPNs).

Dr Butler has been awarded the Albert Baikie Memorial Medal from the Haematology Society of Australia and New Zealand (HSANZ) for the best young investigator at the national annual Blood 2022 meeting in Sydney in September. The award is given to recognise the best presentation, either oral or poster, at the Annual Scientific Meeting by a new investigator who is a financial member of HSANZ. The winner receives a $5,000 prize and is presented with the Albert Baikie Memorial Medal. This prestigious award is open to new investigators who were awarded their postgraduate qualification (MSc, FRACP, FRCPA or PhD) within the past 5 years.

Community access cutting edge research at the CCS

Community representatives were very engaged with the presentation

Community and Researcher Engagement, Myeloproliferative Neoplasms, 2022

by Dr Juliana de Castro, CaRE committee member

The Community and Researcher Engagement (CaRE) program from the Central Clinical School at Monash University hosted a hybrid seminar called ‘Myeloproliferative Neoplasms – Towards Precision Medicine’ at the Betty & John Laidlaw Education & Innovation Hub on Thursday, 13 October 2022.

CaRE in action: patients key to blood cancer lobbying success: Rare Disease Day feature

L-R: Patient advocate Ken and researcher Professor Andrew
Perkins talk about the experience of living with the illness and
the challenges of research into the disease. Video (2:19 mins)

Part of our special series for Rare Disease Day featuring patient advocates and CCS researchers  

Clinician-scientist Professor Andrew Perkins, who heads the Blood Cancer Genomics team at the ACBD, has for 12 years researched myeloproliferative neoplasms (MPNs). MPNs are a diverse group of chronic blood cancers. Myelofibrosis (MF) is at the severe end of the spectrum.